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OBJECTIVE—The purpose of the current study was to deter-
mine whether double-stranded adeno-associated virus (dsAAV)-
mediated in vivo expression of -cell growth factors, glucagon-
like peptide-1 (GLP-1) and the NK1 fragment of hepatocyte
growth factor (HGF/NK1) in -cells, improves pathology in the
db/db mouse model of type 2 diabetes.
RESEARCH DESIGN AND METHODS—The glucoregulatory
actions of GLP-1 and full-length HGF are well characterized.
Here, we test the ability of HGF/NK1 to induce proliferation of
exogenous islets and MIN6 -cells. In addition, we target both
GLP-1 and HGF/NK1 to endogenous -cells using dsAAV vectors
containing the mouse insulin-II promoter. We compare the
abilities of these gene products to induce islet proliferation in
vitro and in vivo and characterize their abilities to regulate
diabetes after AAV-mediated delivery to endogenous islets of
db/db mice.
RESULTS—Recombinant HGF/NK1 induces proliferation of iso-
lated islets, and dsAAV-mediated expression of both GLP-1 and
HGF/NK1 induces signiﬁcant -cell proliferation in vivo. Further-
more, both GLP-1 and HGF/NK1 expressed from dsAAV vectors
enhance -cell mass and insulin secretion in vivo and signiﬁ-
cantly delay the onset of hyperglycemia in db/db mice.
CONCLUSIONS—A single treatment with dsAAV vectors ex-
pressing GLP-1 or HGF/NK1 enhances islet growth and signiﬁ-
cantly improves pathology in a mouse model of type 2 diabetes.
This represents the ﬁrst example of a successful use of HGF/NK1
for diabetes therapy, providing support for direct AAV-mediated
in vivo delivery of -cell growth factors as a novel therapeutic
strategy for the treatment of type 2 diabetes. Diabetes 59:
3108–3116, 2010
A
promising therapeutic for type 2 diabetes is
the incretin family of proteins, particularly
glucagon-like peptide-1 (GLP-1) (1). GLP-1
has a variety of glucoregulatory actions,
which include enhancing insulin synthesis and secre-
tion, improving insulin sensitivity, inhibiting glucagon
secretion, and increasing -cell mass (2). However,
GLP-1 is rapidly degraded by the ubiquitous enzyme,
dipeptidyl peptidase-IV, and thus has a short in vivo
half-life that limits its therapeutic efﬁcacy (3). We have
recently shown that adeno-associated virus (AAV) ad-
ministration of GLP-1 provides long-term, high-level
GLP-1 expression, offering an alternative approach to
peptide therapy (4).
Another protein that has potential as a therapeutic for
diabetes is hepatocyte growth factor (HGF). HGF is
involved in the regeneration of multiple organs, includ-
ing the liver, kidney, and lung (5), and a number of
studies illustrate the efﬁcacy of HGF in animal models of
diabetes (6–10). Transgenic mice speciﬁcally overex-
pressing HGF in -cells exhibit increased -cell prolif-
eration, function, and survival (5), and HGF improves
islet transplant outcome in rodent models (6,7). More-
over, HGF has previously been delivered to isolated
islets via adenovirus gene transfer, reducing -cell
death, reducing the minimal islet mass required for
successful transplant, and improving overall transplant
outcome (8,9).
While full-length HGF has beneﬁcial effects in animal
models of diabetes, recent research has focused specif-
ically on the N and K1 domains of HGF (HGF/NK1).
HGF/NK1 comprises the NH2-terminal 175 amino acids
of HGF and is sufﬁcient for binding and partial activa-
tion of the HGF receptor, as well as initiation of some
mitogenic activity (11–13). HGF/NK1 has not previously
been studied in relation to diabetes but may provide
several advantages over full-length HGF. HGF/NK1 may
improve the safety proﬁle compared with full-length
HGF by limiting stimulation of the HGF receptor, Met.
Another advantage of using HGF/NK1 instead of full-
length HGF is the ability to use double-stranded AAV
(dsAAV) vectors for gene delivery. dsAAV vectors pro-
vide rapid, efﬁcient, and stable gene expression (14),
without the immunogenicity associated with adenovirus
vectors. However, dsAAV vectors have limited packag-
ing capacity, thus preventing their use for delivery of
full-length HGF.
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to enhance islet function or survival have used ex vivo
transduction protocols. However, in vivo transduction
of -cells has been achieved by direct targeting of genes
to -cells of pancreatic islets using dsAAV vectors
(4,15). There are many beneﬁts of direct in vivo gene
transfer compared with transduction of islets for trans-
plantation, as well as compared with existing therapeu-
tics. First of all, the applicability of islet transplantation
is reduced by the limited availability of islets. Secondly,
while existing antidiabetic agents and incretin drugs
have therapeutic efﬁcacy, they are often associated with
adverse effects and multiple daily administrations. Di-
rect in vivo gene transfer could be cost-effective and
beneﬁcial to patients’ quality of life because it may be
therapeutic in as little as a single treatment.
Here, we examine whether in vivo delivery of the
growth factors GLP-1 and HGF/NK1 via dsAAV-mediated
gene transfer can improve pathology in a mouse model of
type 2 diabetes. We demonstrate that dsAAV-expressed
GLP-1 and HGF/NK1 enhance islet proliferation and delay
onset of diabetes in db/db mice, providing the ﬁrst evi-
dence that HGF/NK1 is a potential therapeutic for
diabetes.
RESEARCH DESIGN AND METHODS
Cells, plasmids, and viruses. The MIN6 -cell line was a gift from Dr.
Jun-ichi Miyazaki of the Osaka University Medical School. MIN6 cells were
cultured in high-glucose Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C in
a5 %C O 2 atmosphere.
The plAdeno5 adenovirus helper plasmid, the AAV8 helper plasmid expressing
the AAV8 cap and AAV2 rev genes, and the double-stranded AAV8 plasmid
expressing enhanced green ﬂuorescent protein (eGFP) ﬂanked by inverted-
terminal repeats under the control of the cytomegalovirus (CMV) promoter were
gifts of Dr. Hiroyuki Nakai of the University of Pittsburgh. cDNA for full-length
murine HGF was a gift from Dr. Andrew Stewart of the University of Pittsburgh.
The NK1 fragment of HGF was obtained by PCR using primers 5-CATCAGAC-
CGGTGGATCCAGCCATGATGTGGGGGACCAAACTTCT and 5-GCGGCCGCG-
GATCCCTATTACAACTTGTATGTCAAAATTACTTTGTGTATCC, which introduced
AgeI and NotI sites, respectively. The dsAAV–CMV–eGFP expression plasmid was
subsequently modiﬁed to express our transgenes of interest under the control of the
murine preproinsulin-II promoter (MIP). The CMV promoter was excised using
restriction enzymes MluI and KpnI. Subsequently, plasmid expressing genes of
interest expressed between Adeno-associated virus inverted terminal repeats
(pAAV)–MIP–GLP1 was generated by excising eGFP with restriction enzymes AgeI
and XbaI, as previously described (4), and pAAV–MIP–HGF/NK1 was generated by
excising eGFP with AgeI and NotI.
Recombinant dsAAV vectors were generated according to the triple
transfection protocol as previously described (16). Brieﬂy, HEK293 cells were
transfected with the plAdeno5, AAV8 helper, and dsAAV expression plasmids.
Virions were puriﬁed by double CsCl gradient centrifugation, and viral
genomes were quantitated by dot blot analysis. For the remainder of this
manuscript, these vectors will be referred to as dsAAV–eGFP, dsAAV–GLP1,
and dsAAV–NK1, respectively.
Animal studies. Female C57BL/6 and db/db mice were obtained from
Jackson Laboratories (Bar Harbor, ME). All experiments were approved by
the University of Pittsburgh Animal Care and Use Committee. Mice were
maintained on a standard 12 h light/dark cycle and received a standard diet.
Infections were carried out at a dose of 4  10
11 viral genomes (vg) per mouse.
Viruses were administered intraperitoneally in a total volume of 800 lo f
sterile saline solution supplemented with 5% sorbitol. Insulin tolerance tests
were performed by intraperitoneal administration of 1 unit/kg of insulin (gift
of Dr. Rita Bottino, University of Pittsburgh Diabetes Institute) after a 6-h fast.
Blood glucose monitoring was carried out at indicated time points on
restrained, unanesthetized animals via tail vein bleeds.
Mouse islet isolation. Ex vivo islet growth studies were performed using
islets freshly isolated from 6-week-old female C57BL/6 mice. Islets were
isolated as previously described (17). Brieﬂy, after laparotomy, cold collage-
nase (type V, 1.75 mg/ml, Sigma Chemical Co., St. Louis, MO) was used to
inﬂate the pancreas via injection into the common bile duct. After inﬂation,
the pancreas was removed and incubated for 20 min at 37°C. Islets were
puriﬁed by Ficoll density gradient centrifugation and hand-picked under a
stereomicroscope, and the purity of the islets was determined by Dithizone
staining. Islets were maintained in RPMI-1640 media supplemented with 10%
heat inactivated FBS, 2 mmol/l L-glutamine, 100 units/ml penicillin, and 100
g/ml streptomycin in a humidiﬁed 5% CO2 incubator at 37°C.
Tritiated-thymidine proliferation assays. Recombinant HGF (rHGF) and
recombinant HGF/NK1 (rNK1) were gifts of Dr. Donald Bottaro of the
National Institutes of Health. Freshly isolated islets were plated at 100
islets/well in six well dishes and treated with 10 go r2 0g of rHGF or rNK1,
respectively, for a period of 96 h. After incubation with recombinant proteins,
islets were washed and incubated at 37°C and 5% CO2 overnight in complete
media containing 1 Ci of
3H-thymidine. Islets were subsequently washed and
lysed. Lysates were absorbed onto ﬁberglass ﬁlter paper, and counts per min
were obtained using a Wallac 1,205 Betaplate liquid scintillation counter
(PerkinElmer, Waltham, MA).
ELISAs. MIN6 -cells were grown to 80% conﬂuency in a 6-well dish, then
infected with dsAAV–eGFP, dsAAV–GLP1, or dsAAV–NK1 in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% FBS and incubated at 37°C
and 5% CO2 for 12–24 h. Media was then removed from the cells, and protein
secretion was measured via ELISA. For GLP-1, the GLP-1(7–36) Active ELISA
Kit (Linco Research, St. Charles, MO) was used. The anti-sera in this assay
cross-react 100% with GLP-1(7–37), GLP-1(7–36), and GLP-1(9–36). The detection
limit of this assay is 3 mmol l
1. For HGF, a standard sandwich ELISA was
developed using anti-HGF (N-17) (Santa Cruz Biotechnology, Santa Cruz,
CA) as the capture antibody and biotinylated anti-mHGF (R&D Systems,
Minneapolis, MN) as the detection antibody. Each of these antibodies recog-
nizes the NH2 terminus of HGF, including the NK1 domain, and rNK1 was used
to generate the standard curve. The limit of detection of this assay was 0.1
pg/ml.
Circulating insulin concentrations were determined from db/db mouse
serum samples at 14 weeks of age (10 weeks post-treatment) using a mouse
Insulin Elisa kit (ALPCO, Salem, NH). The sensitivity of this assay is 0.06
ng/ml.
Wounding assays. MIN6 -cells were grown to near conﬂuency in 12-well
plates. A deﬁned area of the monolayer was disrupted with a sterile instru-
ment, and the size was measured microscopically. Cells were then infected
with the eGFP or HGF/NK1 virus or were treated with rHGF or rNK1. Wound
size was measured again at 24 and 48 h post-treatment. MetaMorph software
(Molecular Devices, Sunnyvale, CA) was used to measure wound size at each
time point.
Microscopy. Immunoﬂourescence staining was carried out on parafﬁn-
embedded tissue sections. Antigen retrieval was performed prior to incuba-
tion with the primary antibodies. For anti-GLP1/insulin double staining,
sections were incubated with a mixture of primary antibodies against GLP-1
(mouse monoclonal; Abcam, Cambridge, MA) and insulin (guinea pig poly-
clonal; Abcam, Cambridge, MA). After incubation with the primary antibodies
and three washes, the mixture of secondary antibodies, consisting of Alexa-
488-conjugated rabbit anti-mouse IgG (Molecular Probes, Eugene, OR) and
Cy3-conjugated donkey anti-guinea pig IgG (Jackson ImmunoResearch, West
Grove, PA), were added. Cell nuclei were counterstained with DAPI (Sigma,
St. Louis, MO). In addition, multiple antibodies against HGF were unsuccess-
fully tested for their ability to detect HGF via immunoﬂuorescence, including
goat anti-HGF (N-17) (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit
anti-HGF (H-145) (Santa Cruz Biotechnology, Santa Cruz, CA), and goat
anti-mHGF (R&D Systems, Minneapolis, MN). Lack of HGF detection via
immunoﬂuorescence is likely due to poor immunoreactivity of the tested
antibodies in this protocol.
The relative -cell area was determined by measuring the areas of
insulin-stained islets using MetaMorph software (Molecular Devices, Sunny-
vale, CA). -cell mass was determined using the following formula: -cell mass
(mg)  area of insulin-stained islets/total pancreatic area  total pancreas
weight.
Statistical analyses. Statistical analysis was performed using the Stata 8.2
(STATA, College Station, TX) software package, and the data collected are
expressed as mean 	 SEM. For most analyses, P values were determined
using the Student t test. The percentage of nondiabetic mice was calculated by
Kaplan–Meier survival analysis. A P value of 
0.05, arrived at using ANOVA
and log rank test, was considered to indicate a statistically signiﬁcant
difference.
RESULTS
Recombinant HGF/NK1 enhances islet proliferation
ex vivo. Previous research has shown that both GLP-1
and full-length HGF are capable of enhancing the mass
of murine islets (6,18). To use HGF/NK1 for insertion
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examined the ability of rNK1 to stimulate proliferation
of islets compared with rHGF. Islets were isolated from
6-week-old female C57BL/6 mice as described in the
Research Design and Methods and subsequently treated
for 96 h with the indicated concentrations of rHGF or
rNK1 (Fig. 1). After 96 h, levels of islet proliferation
were measured using a
3H-thymidine proliferation as-
say. As expected, full-length rHGF provided the maxi-
mum observed levels of islet proliferation, at 4.5- to
5.5-fold above background. Moreover, rNK1 induced
signiﬁcant increases in islet proliferation at the 10 and
20 ng doses, 2.75- and 4-fold above background,
respectively. Interestingly, the difference in prolifera-
tion induced by rHGF and rNK1 at the 20 ng dose was
not statistically signiﬁcant. This suggests that, at higher
doses, the proliferation-inducing potential of HGF/NK1
may be similar to that of full-length HGF in islets.
Expression of GLP1 and HGF/NK1 from dsAAV vec-
tors in MIN6 -cells. To determine whether local
expression of GLP-1 and HGF/NK1 in endogenous
-cells would promote -cell proliferation and improve
diabetes pathology, dsAAV8 vectors were generated
expressing GLP-1 (dsAAV–GLP1) or HGF/NK1 (dsAAV–
NK1) under the regulation of the MIP, as described in
Research Design and Methods. Additionally, dsAAV–
eGFP was generated and used as a negative control. To
measure expression of the -cell growth factors from
the viruses, MIN6 -cells were infected at a dose of 5 
10
4 vg/cell. At 24 h postinfection, the levels of GLP-1 and
HGF/NK1 secreted into the media were determined
using ELISA. The levels of GLP-1 secreted from MIN6
cells infected with dsAAV–GLP1 (508 	 81 pmol/l) were
4 times greater than levels detected in cells infected
with the dsAAV–eGFP (124 	 27 pmol/l; Fig. 2A).
Similarly, infection with dsAAV–NK1 resulted in a 2.5-
fold increase in HGF/NK1 expression (285 	 51 pmol/l)
compared with cells infected with the eGFP control
virus (113 	 1.8 pmol/l; Fig. 2B).
It is known that full-length HGF enhances healing of
wounded CCL53.1 cell monolayers (19). Thus, to mea-
sure the activity of HGF/NK1 expressed from the dsAAV
vector, wounding assays were performed using MIN6
cells as described in Research Design and Methods. The
effects on wound size at 24 and 48 h post-treatment with
rHGF, rNK1, dsAAV–eGFP, and dsAAV–NK1 were cal-
culated as the ratio to the original wound size at 0 h. As
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FIG. 1. rHGF/rNK1 induces proliferation of islets ex vivo. Freshly
isolated islets were treated with 10 or 20 ng of rHGF or rNK1 for a
period of 96 h. Islet proliferation was determined by measuring
3H-thymidine incorporation. Data are expressed as the fold change
above untreated cells  SEM for three independent experiments. *P <
0.05 relative to untreated islets.
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FIG. 2. Biologically active HGF/NK1 is expressed from a dsAAV8 vector at levels similar to GLP-1. dsAAV vectors express high levels of GLP-1 (A)
and HGF/NK1 (B) in MIN6 -cells. C: Wounding assays were performed using MIN6 -cells to assess the biological activity of dsAAV-expressed
HGF/NK1. dsAAV-NK1 (black squares) induced the greatest wound restitution compared with dsAAV–eGFP (black diamonds), rHGF (open
triangles), and rNK1 (open squares). D: dsAAV–NK1 induced an 30% reduction in wound size at 24 h postinfection (gray bars) and an 60%
reduction in wound size at 48 h postinfection (white bars) compared with initial wound size (black bars). Data depict means of three independent
experiments  SEM. *P < 0.05.
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and 48 h was observed after treatment with rHGF, rNK1,
and dsAAV–NK1, but not dsAAV–eGFP. The greatest
restitution of the wound was observed in dsAAV–NK1-
infected samples, improving from a wound size at0ho f
130  10
4 	 12  10
4 m
2 to 81  10
4 	 5.8  10
4 m
2
at 24 h (31% decrease), and 46  10
4 	 5.2  10
4 m
2 at
48 h (60% decrease). These results demonstrate the
biological activity of HGF/NK1 expressed from the
AAV-transduced MIN6 cells.
Expression of GLP1 from dsAAV vectors is restricted
to islets. Expression of transgenes under the control of
the MIP should restrict expression to insulin-producing
-cells. To examine the tissue-speciﬁc expression of
GLP-1 and HGF/NK1, pancreas sections from db/db mice
at 10 weeks post-treatment with dsAAV-GLP1 and
dsAAV-NK1 were stained for GLP-1 and HGF/NK1. Ex-
pression was analyzed via immunoﬂuorescence confo-
cal microscopy, as described in Research Design and
Methods. We have previously demonstrated that the
anti-GLP-1 antisera used in this study cross-reacts with
proglucagon, thereby marking all -cells, as well as cells
expressing immunoreactive GLP-1 (4). To identify
-cells expressing viral-encoded GLP-1, sections were
costained with insulin. Only mice treated with dsAAV–
GLP1 (Fig. 3) contained cells that were immunoreactive
for both insulin and GLP-1 (white arrows), with 8.5 	
1.5% of -cells expressing GLP-1. However, expression
of HGF/NK1 was not observed in islets via immunoﬂu-
orescence (not shown), due to poor immunoreactivity
of the antibodies against the NK1 fragment tested in this
method. Furthermore, no GLP-1, HGF/NK1, or eGFP
expression was observed in liver or spleen (not shown),
indicating that these viruses are speciﬁc for insulin-
producing -cells.
In vivo expression of GLP-1 and HGF/NK1 delays
onset of diabetes in db/db mice. To examine possible
therapeutic effects of GLP-1 and HGF/NK1 expression
from endogenous -cells on the course of type 2 diabe-
tes, 4-week-old female db/db mice were treated with
a single intraperitoneal injection of dsAAV–eGFP,
dsAAV–GLP1, or dsAAV–NK1 and blood glucose levels
FIG. 3. dsAAV-expressed GLP-1 is localized to insulin-producing
-cells. Expression of GLP-1 in db/db mice treated with dsAAV–eGFP
(A) and dsAAV–GLP1 (B) was examined by immunoﬂuorescence at 14
weeks of age, or 10 weeks post-treatment. Islets from mice treated
with dsAAV–GLP1 contained examples of -cells (indicated by white
arrows) that were positive for both GLP-1 (green) and insulin (red).
Islets from mice treated with dsAAV–eGFP contained no examples of
GLP-1 and insulin double-positive cells, indicating that the green
staining observed in these samples is glucagon from pancreatic -cells.
Data are representative of at least two sections per mouse, n  10 mice
per group. Scale bar  100 m in all images. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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FIG. 4. GLP-1 and HGF/NK1 gene transfer prolong normoglycemia in db/db mice. Four-week-old female db/db mice were injected intraperitoneally
with 4  10
11 vg of dsAAV–eGFP (A; n  10), dsAAV–GLP1 (B; n  10), or dsAAV–NK1 (C; n  10), and blood glucose levels were monitored
weekly until all mice became hyperglycemic. D: The percentage of diabetes-free animals, deﬁned as having blood glucose levels < 280 mg/dl, are
plotted against age. Although there was no difference in the incidence of diabetes, there was a signiﬁcant delay in the onset in mice treated with
dsAAV–GLP1 (open triangles) and dsAAV–NK1 (open circles) compared with dsAAV–eGFP-infected control animals (black squares). A P value
of <0.005 by log rank test analysis was used to indicate a statistically signiﬁcant percentage of normoglycemic animals.
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tes. As shown in Fig. 4A and D, 100% of mice receiving
the eGFP control virus developed diabetes by 7 weeks
of age. However, treatment with the GLP-1 virus signif-
icantly delayed onset of disease, with mice remaining
normoglycemic as late as 10 weeks of age (Fig. 4B and
D). An even greater effect was observed in animals
receiving the HGF/NK1 virus (Fig. 4C and D), with
animals remaining normoglycemic as late as 14 weeks of
age, twice as long as control mice. These data show that,
although the frequency of onset of hyperglycemia was
not reduced, a single treatment with AAV expressing
-cell growth factors was sufﬁcient to prolong normo-
glycemia in db/db mice.
GLP-1 and HGF/NK1 gene transfer enhances -cell
proliferation and survival in db/db mice. GLP-1 and
HGF have previously been shown to promote -cell
proliferation and survival (2,6–10). To determine
whether dsAAV-mediated expression of these growth
factors has a similar effect in db/db mice, -cell prolif-
eration was measured in db/db mice at 10 weeks postin-
fection with dsAAV–eGFP, dsAAV–GLP1, or dsAAV–
NK1 by analysis of Ki67/insulin cells in pancreatic
sections (Fig. 5A). Figure 5B shows quantiﬁcation of
Ki67 expression, illustrating a signiﬁcant increase in
Ki67 -cells after infection with the GLP-1 and NK1
viruses.
Transferase-mediated dUTP nick-end labeling (TUNEL)
staining was performed on pancreatic sections from db/db
mice at 10 weeks post-treatment to measure -cell sur-
vival. As shown in Fig. 5C and D, there was a signiﬁcant
decrease in the percentage of TUNEL/insulin cells
after infection with dsAAV–GLP1 and dsAAV–NK1, com-
pared with the control virus. Taken together, these results
suggest that dsAAV-mediated expression of GLP-1 and
HGF/NK1 promotes -cell proliferation and survival in
db/db mice.
dsAAV-mediated expression of GLP-1 and HGF/NK1
increases -cell mass in db/db mice. Enhanced -cell
proliferation and survival after infection with dsAAV-
expressing GLP-1 and HGF/NK1 suggests an increase in
-cell mass in response to these growth factors. There-
fore, -cell mass was analyzed at 14 weeks of age. There
was a signiﬁcant increase in -cell mass in db/db mice
(Fig. 6A) treated with dsAAV–GLP1 (3.4 	 1.1 mg) and
dsAAV–NK1 (4.5 	 1.0 mg), compared with control mice
(1.5 	 0.5 mg).
In addition to larger islets, GLP-1 and HGF have been
indicated to promote -cell neogenesis. When combined
with the suppression of -cell apoptosis (Fig. 5), this
FIG. 5. Gene transfer of GLP-1 and HGF/NK1 increase -cell proliferation in db/db mice. A: Pancreatic sections from db/db mice infected with
dsAAV–eGFP, dsAAV–GLP, or dsAAV–NK1 were stained for insulin (red) and the proliferation marker, Ki67 (green). Arrowheads indicate cells
that are double-positive for insulin and Ki67. B: Quantiﬁcation of Ki67-positive -cells, expressed as the mean percentage of Ki67-positive,
insulin-positive cells in 20–40 individual islets from each group. *P < 0.05. C: Pancreatic sections from db/db mice infected with dsAAV–eGFP,
dsAAV–GLP, or dsAAV–NK1 were stained for insulin (red) and subjected to TUNEL staining (green). Arrowheads indicate cells that are
double-positive for insulin and TUNEL. D: Quantiﬁcation of TUNEL-positive -cells, expressed as the mean percentage of TUNEL-positive,
insulin-positive cells in 20–40 individual islets from each treatment group. *P < 0.002. For all images, magniﬁcation  40, scale bars  100 m.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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determine whether dsAAV–GLP1 and dsAAV–NK1 in-
crease overall numbers of islets, tissue sections from
treated mice were analyzed for numbers of islets and
compared with control mice. As shown in Fig. 6B, there
was a modest, but not signiﬁcant, increase in numbers
of islets in mice treated with dsAAV–GLP1 but not
dsAAV–NK1, compared with mice receiving dsAAV–
eGFP. Taken together, data in Figures 4 and 5 indicate
that the observed increase in -cell mass is due to
enhanced proliferation of -cells in existing islets, not
-cell neogenesis.
-Cell-speciﬁc expression of GLP-1 and HGF/NK1
increases insulin secretion, but not insulin sensitiv-
ity, in db/db mice. Previous research has shown that
GLP-1 and HGF are capable of increasing insulin synthesis
and secretion, as well as enhancing insulin sensitivity
(2,5). Serum insulin levels were evaluated in 14-week-old
db/db mice (Fig. 6C). There was a signiﬁcant increase in
basal circulating insulin levels in mice treated with
dsAAV–NK1 compared with dsAAV–eGFP. In addition,
there was a modest, but not signiﬁcant (P  0.054),
increase in basal circulating insulin in mice treated with
dsAAV–GLP1.
To evaluate insulin sensitivity, intraperitoneal insulin
tolerance tests were performed as described in Research
Design and Methods. At the time of treatment (4 weeks of
age, open symbols), db/db mice were already insulin-
resistant (Fig. 6D). Furthermore, by 14 weeks of age
(closed symbols), infection with dsAAV vectors express-
ing eGFP, GLP-1, and HGF/NK1 was not able to overcome
the severe insulin resistance.
In vivo expression of GLP-1 and HGF/NK1 does not
affect weight of obese db/db mice. GLP-1 inhibits
gastric emptying and gastric acid secretion in humans and
rodent models, leading to decreased food intake and
reduced body weight (18,20). To assess the effects of
dsAAV-expressed GLP-1 and HGF/NK1 on body weight,
the weights of db/db mice treated at 4 weeks of age were
monitored weekly (Fig. 7). At 6 weeks of age, there was a
modest, but statistically signiﬁcant, difference in body
weights, with dsAAV–GLP1- and dsAAV–NK1-infected
mice weighing 7–10 g less than mice treated with
dsAAV–eGFP. However, there was no difference in body
weight at any other time point.
DISCUSSION
We demonstrated previously that dsAAV8 vectors pro-
vide long-term, stable gene transfer and expression in
pancreatic -cells in C57BL/6 and BALB/c mice (15).
Expression of transgenes can be restricted to -cells by
coupling transgene expression to the MIP. Moreover,
our dsAAV8 vector expressing GLP-1, driven by the MIP,
provides local production and secretion of GLP-1 in pancre-
atic -cells and prevents diabetes after multiple low-dose
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FIG. 6. GLP-1 and HGF/NK1 gene transfer increases -cell mass and
insulin secretion in db/db mice. A: -Cell mass was evaluated as
described in Research Design and Methods. B: The average numbers of
islets in db/db mice did not differ signiﬁcantly among any of the three
treatments. Data are presented as the mean  SEM of at least two
sections per mouse, n  10 mice per group. C: ELISAs performed on
serum from treated mice revealed a signiﬁcant increase in circulating
insulin levels in db/db mice treated with dsAAV–NK1. The increased
insulin after dsAAV–GLP1 administration was not statistically signiﬁ-
cant (P  0.054). D: Intraperitoneal insulin tolerance tests performed
at the time of treatment (4 weeks of age) and 10 weeks post-treatment
(14 weeks of age), as described in Research Design and Methods,
indicate insulin resistance at each time point. *P < 0.05; **P < 0.01.
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FIG. 7. dsAAV-mediated expression of GLP-1 and HGF/NK1 does not
affect the weight of obese db/db mice. The weights of female db/db mice
treated with dsAAV–eGFP (black squares; n  10), dsAAV–GLP1 (open
triangles; n  10), and dsAAV–NK1 (open circles; n  10) were
monitored weekly. A signiﬁcant difference in weights of dsAAV–GLP1
and dsAAV–NK1 infected mice was observed at 6 weeks of age but at no
other time points. *P < 0.05.
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diabetes (4).
Here, we examined the efﬁcacy of the GLP-1–express-
ing dsAAV8 vector as well as a dsAAV8 vector express-
ing HGF/NK1 in a mouse model for type 2 diabetes.
Full-length HGF is a large protein, encoded by an 2.2
kb gene. The packaging capacity of dsAAV vectors is
restricted to 2.5 kb, including gene and promoter, thus
preventing expression of the full-length HGF gene.
HGF/NK1 possesses about 50% of the mitogenic activity
of full-length HGF in hepatocytes (11), but its effects in
-cells have not been examined. Here, we demonstrate
that dsAAV8 vectors provide high levels of GLP-1 and
HGF/NK1 expression in vitro, and that this expression is
speciﬁc to -cells. In addition, while we have previously
shown that dsAAV-GLP1 induces -cell proliferation (4),
here we demonstrate that rNK1 and HGF/NK1 expressed
from a dsAAV8 vector are capable of inducing -cell
proliferation. Moreover, expression of GLP-1 and HGF/
NK1 by endogenous -cells after dsAAV8 gene transfer
enhances -cell mass in vivo and signiﬁcantly delays the
onset of diabetes in db/db mice.
Gene therapy provides a potentially very useful
method of targeted expression of GLP-1 and HGF to
-cells. A number of studies have examined the poten-
tial of endogenous expression of GLP-1 and HGF to
mitigate diabetes in animal models. Previous studies
using GLP-1 gene therapy for type 2 diabetes have
primarily used constitutive promoters, such as CMV,
chicken -actin, or ubiquitin promoters, to drive unreg-
ulated expression of GLP-1. Although these studies have
yielded promising results, with improved insulin sensi-
tivity and lowered blood glucose levels, these treat-
ments have also resulted in high levels of circulating
GLP-1, which may promote GLP-1 receptor desensitiza-
tion over time. The vector used in our study provides the
advantage of local GLP-1 expression by using the MIP to
restrict expression to -cells, the primary target of GLP-1 for
glucoregulatory activity, and limiting levels of circulating
GLP-1 (4).
Diabetes gene therapy also has been attempted using
vectors expressing HGF, mostly in ex vivo studies to
facilitate islet transplantation. HGF expression has been
restricted to islets by using adenovirus vectors driven by
the rat insulin promoter, demonstrating that targeted
HGF gene transfer reduces -cell death, reduces the
minimal islet mass required for successful transplant,
and improves overall transplant outcome (8,9). HGF
also can regulate diabetes in a type 2 diabetes mouse
model, and HGF gene transfer slows the progression of
diabetic nephropathy in db/db mice. Each of these
studies has used full-length HGF as a therapeutic gene.
Here, we provide the ﬁrst evidence that HGF/NK1 has
therapeutic efﬁcacy in an animal model of diabetes.
HGF/NK1 may provide several advantages over full-
length HGF. The receptor for HGF is Met, which is
encoded by the proto-oncogene, c-Met. Although the
HGF-Met pathway is known to play a role in tumorigen-
esis, little is known about the possible role of HGF/NK1
in this pathway. Several studies indicate that HGF/NK1
is antagonistic, suggesting a role for HGF/NK1 as a
potential cancer therapy (21,22). Other studies, includ-
ing work presented here, suggest that HGF/NK1 is a
partial agonist, capable of inducing 50% of mitogenic
activity of full-length HGF (11–13). The partial agonist
effect of HGF/NK1 may have a role in improving its
safety proﬁle compared with full-length HGF. Indeed,
while transgenic mice that systemically overexpress
HGF/NK1 developed complications similar to those seen
in full-length HGF transgenic mice, including increased
susceptibility to some cancers, the HGF/NK1 pheno-
types were signiﬁcantly less severe than those seen in
full-length HGF transgenic mice (13). Moreover, trans-
genic mice overexpressing HGF speciﬁcally in -cells
have not been associated with increased risk of tumor-
igenesis (A.F. Stewart, personal communication), sug-
gesting that localized expression of HGF and HGF/NK1
may further enhance their safety.
Another advantage of using HGF/NK1 instead of full-
length HGF is the ability to use dsAAV vectors for gene
delivery. All of the GLP-1 and HGF gene transfer studies
cited above have used adenovirus vectors. Whereas
adenovirus vectors provide rapid and efﬁcient gene
transfer, their immunogenicity limits their therapeutic
potential. Although the packaging capacity of dsAAV
vectors is limited, a variety of factors contribute to the
attractiveness of these vectors for gene transfer. First of
all, AAV has not been associated with any disease or
pathology. Furthermore, unlike adenovirus, there is a
lack of a signiﬁcant immune response directed against
the AAV vector, contributing to the ability of the vectors
to persist in vivo (23,24). AAV vectors also provide
long-term transgene expression, primarily via the forma-
tion of double-stranded extrachromosomal (episomal)
genomes (25,26). This suggests that dsAAV-mediated
production of GLP-1 and HGF/NK1 in -cells may abro-
gate the need for repeat administrations, which are re-
quired with current therapies.
Our results demonstrate that dsAAV gene transfer of
the growth factors, GLP-1 and HGF/NK1, signiﬁcantly
improves pathology in db/db mice. Although the fre-
quency of onset of hyperglycemia was not reduced, a
single treatment with dsAAV expressing GLP-1 and
HGF/NK1 was sufﬁcient to increase -cell mass and
insulin secretion and prolong normoglycemia. These
phenotypes were observed despite suboptimal in vivo
expression of GLP-1 and presumably HGF/NK1. This is
probably due to the nature of GLP-1 and HGF/NK1,
which are secreted paracrine factors that likely inﬂu-
ence neighboring islets and untransduced -cells within
each islet. There are a number of methods by which this
technique may be optimized to improve expression,
thereby possibly improving efﬁcacy. First of all, the dose
of 4  10
11 vg/mouse was chosen to test a low dose of
vector expressing a therapeutic transgene. However, we
have previously demonstrated that doses as high as 10
12
vg of dsAAV8 expressing eGFP were unable to achieve
complete transduction of islets, with a gradient of
expression observed with higher efﬁciency in the pe-
ripheral zone than in the central zone (15), similar to the
GLP-1 expression patterns observed here. Therefore,
higher doses of virus may provide enhanced transduc-
tion of -cells. This may be particularly true in obese
mice, as additional virus may be necessary to compen-
sate for substantially increased body weight. Further-
more, intraperitoneal injection of virus was chosen for
ease of administration. However, we have previously
demonstrated that retrograde pancreatic intraductal de-
livery, which is similar to the commonly used clinical
technique of endoscopic retrograde cholangiopancre-
atography, provides enhanced transduction of -cells
within islets (15). Therefore, this approach, while more
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more clinically relevant than the more commonly used
intraperitoneal injection.
Previous studies indicate that GLP-1 and HGF are
capable of enhancing insulin sensitivity (5), and that
GLP-1 is capable of regulating food intake, thereby
reducing body weight in obese patients (18,27). This
was not the case in the studies presented here, as
neither GLP-1 nor HGF/NK1 reversed insulin resistance
at the tested time points or prevented weight gain in
db/db mice. In regard to insulin sensitivity, it is possible
that the severity of insulin resistance observed at the
time of treatment precluded compensation by the ob-
served functional increase in -cell mass. It also may be
possible that insulin sensitivity was increased sufﬁ-
ciently at earlier times post-treatment to allow the
increased levels of circulating insulin to delay the onset
of hyperglycemia. Alternatively, the localized expres-
sion of these growth factors to the pancreas may
prevent their interaction with other tissues, such as
lipocytes, muscle, and liver, that are important for
controlling insulin sensitivity, thereby preventing the
reversal of insulin resistance. Along these same lines,
GLP-1 is normally produced in and secreted from intes-
tinal endocrine L-cells, which are located mainly in the
distal ileum and colon. GLP-1 then acts locally in the gut
to inhibit gastric emptying and gastric acid secretion,
leading to decreased food intake and reduced body
weight (18,20,28,29). However, restriction of exogenous
GLP-1 expression to -cells likely prevents its gastroin-
testinal effects, as our previous studies with this vector
demonstrate that GLP-1 expressed in -cells from
dsAAV vectors does not increase levels of GLP-1 in
circulation (4). Therefore, although more work is nec-
essary to elucidate the complete mechanism, the data
presented here demonstrate that dsAAV vectors ex-
pressing the growth factors, GLP-1 and HGF/NK1, have
potential as novel therapies for type 2 diabetes.
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